Integra Historical Income Statement

IART Stock

USD 24.54 0.84 3.54%

Historical analysis of Integra LifeSciences income statement accounts such as Total Revenue of 1.6 B or Gross Profit of 458 M can show how well Integra LifeSciences Holdings performed in making a profits. Evaluating Integra LifeSciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Integra LifeSciences's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Integra LifeSciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Integra LifeSciences is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

About Integra Income Statement Analysis

Integra LifeSciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Integra LifeSciences shareholders. The income statement also shows Integra investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Integra LifeSciences Income Statement Chart

At this time, Integra LifeSciences' Total Operating Expenses is comparatively stable compared to the past year. Net Income Applicable To Common Shares is likely to gain to about 218 M in 2024, whereas Income Before Tax is likely to drop slightly above 51.6 M in 2024.

Total Revenue Gross Profit Other Operating Expenses Research Development Non Recurring

Total Revenue

Total revenue comprises all receipts Integra LifeSciences generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Integra LifeSciences Holdings minus its cost of goods sold. It is profit before Integra LifeSciences operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Integra LifeSciences. It is also known as Integra LifeSciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Integra LifeSciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Integra LifeSciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

	2021	2022	2023	2024 (projected)
Gross Profit	944.6M	970.3M	888.4M	458.0M
Total Revenue	1.5B	1.6B	1.5B	1.6B

Gross Profit Total Revenue

Integra LifeSciences income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Discontinued Operations	Tax Provision	Interest Income	Extraordinary Items	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.89	0.9	0.76	0.89	0.67	0.56	0.74	0.82	0.9	0.88	0.56	-0.32	0.7	-0.17	0.73	0.64	0.68	0.65	-0.78	-0.63	-0.73	-0.93	-0.71	0.2
Interest Expense	0.89		0.9	0.8	0.89	0.69	0.51	0.65	0.74	0.89	0.88	0.52	-0.31	0.67	-0.23	0.78	0.54	0.56	0.63	-0.72	-0.63	-0.59	-0.8	-0.87	0.29
Total Revenue	0.9	0.9		0.86	1.0	0.73	0.61	0.78	0.81	0.99	0.99	0.63	-0.23	0.69	-0.05	0.84	0.5	0.64	0.72	-0.74	-0.49	-0.59	-0.8	-0.62	0.18
Gross Profit	0.76	0.8	0.86		0.84	0.82	0.51	0.44	0.68	0.8	0.83	0.68	-0.2	0.75	-0.06	0.98	0.5	0.52	0.72	-0.7	-0.46	-0.57	-0.73	-0.63	0.09
Other Operating Expenses	0.89	0.89	1.0	0.84		0.66	0.55	0.8	0.76	0.99	1.0	0.56	-0.23	0.63	-0.11	0.84	0.44	0.61	0.72	-0.73	-0.52	-0.59	-0.79	-0.61	0.2
Operating Income	0.67	0.69	0.73	0.82	0.66		0.78	0.37	0.83	0.66	0.62	0.91	-0.2	0.87	0.29	0.7	0.77	0.65	0.6	-0.66	-0.2	-0.46	-0.68	-0.53	0.01
Ebit	0.56	0.51	0.61	0.51	0.55	0.78		0.57	0.94	0.62	0.49	0.88	-0.1	0.77	0.46	0.35	0.76	0.79	0.39	-0.41	0.1	-0.1	-0.42	-0.27	-0.09
Research Development	0.74	0.65	0.78	0.44	0.8	0.37	0.57		0.71	0.86	0.8	0.37	-0.17	0.38	0.05	0.43	0.32	0.59	0.57	-0.51	-0.3	-0.29	-0.57	-0.28	0.3
Ebitda	0.82	0.74	0.81	0.68	0.76	0.83	0.94	0.71		0.81	0.72	0.85	-0.21	0.83	0.25	0.56	0.8	0.84	0.55	-0.62	-0.2	-0.39	-0.69	-0.49	0.02
Cost Of Revenue	0.9	0.89	0.99	0.8	0.99	0.66	0.62	0.86	0.81		0.98	0.58	-0.23	0.64	-0.04	0.79	0.47	0.66	0.7	-0.7	-0.46	-0.53	-0.76	-0.59	0.2
Total Operating Expenses	0.88	0.88	0.99	0.83	1.0	0.62	0.49	0.8	0.72	0.98		0.5	-0.22	0.59	-0.15	0.84	0.39	0.57	0.73	-0.73	-0.56	-0.6	-0.79	-0.59	0.22
Income Before Tax	0.56	0.52	0.63	0.68	0.56	0.91	0.88	0.37	0.85	0.58	0.5		0.13	0.91	0.45	0.54	0.84	0.74	0.52	-0.56	-0.02	-0.38	-0.56	-0.35	-0.24
Total Other Income Expense Net	-0.32	-0.31	-0.23	-0.2	-0.23	-0.2	-0.1	-0.17	-0.21	-0.23	-0.22	0.13		0.04	0.21	-0.18	0.04	-0.02	-0.06	0.12	0.23	-0.03	0.22	0.24	-0.47
Net Income	0.7	0.67	0.69	0.75	0.63	0.87	0.77	0.38	0.83	0.64	0.59	0.91	0.04		0.04	0.65	0.92	0.66	0.52	-0.59	-0.35	-0.57	-0.72	-0.55	-0.12
Income Tax Expense	-0.17	-0.23	-0.05	-0.06	-0.11	0.29	0.46	0.05	0.25	-0.04	-0.15	0.45	0.21	0.04		-0.17	0.12	0.38	0.05	-0.03	0.74	0.32	0.21	0.33	-0.33
Selling General Administrative	0.73	0.78	0.84	0.98	0.84	0.7	0.35	0.43	0.56	0.79	0.84	0.54	-0.18	0.65	-0.17		0.37	0.43	0.73	-0.68	-0.53	-0.59	-0.71	-0.62	0.12
Net Income From Continuing Ops	0.64	0.54	0.5	0.5	0.44	0.77	0.76	0.32	0.8	0.47	0.39	0.84	0.04	0.92	0.12	0.37		0.69	0.41	-0.52	-0.29	-0.51	-0.67	-0.51	-0.14
Non Operating Income Net Other	0.68	0.56	0.64	0.52	0.61	0.65	0.79	0.59	0.84	0.66	0.57	0.74	-0.02	0.66	0.38	0.43	0.69		0.44	-0.51	-0.04	-0.34	-0.56	-0.4	-0.41
Non Recurring	0.65	0.63	0.72	0.72	0.72	0.6	0.39	0.57	0.55	0.7	0.73	0.52	-0.06	0.52	0.05	0.73	0.41	0.44		-0.81	-0.51	-0.56	-0.71	-0.44	0.2
Discontinued Operations	-0.78	-0.72	-0.74	-0.7	-0.73	-0.66	-0.41	-0.51	-0.62	-0.7	-0.73	-0.56	0.12	-0.59	-0.03	-0.68	-0.52	-0.51	-0.81		0.63	0.78	0.86	0.58	-0.13
Tax Provision	-0.63	-0.63	-0.49	-0.46	-0.52	-0.2	0.1	-0.3	-0.2	-0.46	-0.56	-0.02	0.23	-0.35	0.74	-0.53	-0.29	-0.04	-0.51	0.63		0.75	0.73	0.64	-0.37
Interest Income	-0.73	-0.59	-0.59	-0.57	-0.59	-0.46	-0.1	-0.29	-0.39	-0.53	-0.6	-0.38	-0.03	-0.57	0.32	-0.59	-0.51	-0.34	-0.56	0.78	0.75		0.9	0.58	0.02
Extraordinary Items	-0.93	-0.8	-0.8	-0.73	-0.79	-0.68	-0.42	-0.57	-0.69	-0.76	-0.79	-0.56	0.22	-0.72	0.21	-0.71	-0.67	-0.56	-0.71	0.86	0.73	0.9		0.68	-0.16
Net Interest Income	-0.71	-0.87	-0.62	-0.63	-0.61	-0.53	-0.27	-0.28	-0.49	-0.59	-0.59	-0.35	0.24	-0.55	0.33	-0.62	-0.51	-0.4	-0.44	0.58	0.64	0.58	0.68		-0.2
Reconciled Depreciation	0.2	0.29	0.18	0.09	0.2	0.01	-0.09	0.3	0.02	0.2	0.22	-0.24	-0.47	-0.12	-0.33	0.12	-0.14	-0.41	0.2	-0.13	-0.37	0.02	-0.16	-0.2

Click cells to compare fundamentals

Integra LifeSciences Account Relationship Matchups

Integra LifeSciences income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	114.7M	119.0M	123.7M	121.1M	123.5M	129.7M
Interest Expense	54.0M	71.6M	50.4M	49.6M	51.4M	53.9M
Total Revenue	1.5B	1.4B	1.5B	1.6B	1.5B	1.6B
Gross Profit	952.9M	851.0M	944.6M	970.3M	888.4M	458.0M
Other Operating Expenses	1.4B	1.2B	1.3B	1.3B	1.4B	1.5B
Operating Income	179.0M	151.4M	197.2M	238.9M	111.5M	70.7M
Ebit	91.3M	148.9M	242.7M	270.0M	150.5M	158.0M
Research Development	79.6M	77.4M	93.1M	101.2M	174.6M	183.3M
Ebitda	206.0M	267.9M	366.3M	391.1M	274.0M	287.7M
Cost Of Revenue	564.7M	520.8M	597.8M	587.4M	653.2M	685.8M
Total Operating Expenses	794.2M	699.7M	747.4M	731.4M	836.4M	878.2M
Income Before Tax	60.1M	93.5M	214.7M	213.9M	81.1M	51.6M
Total Other Income Expense Net	(118.9M)	(57.9M)	17.4M	(25.0M)	(30.5M)	(28.9M)
Net Income	50.2M	133.9M	169.1M	180.6M	67.7M	44.1M
Income Tax Expense	9.9M	(40.4M)	45.6M	33.3M	13.3M	7.6M
Selling General Administrative	687.6M	594.5M	637.4M	616.3M	656.6M	339.5M
Net Income Applicable To Common Shares	50.2M	133.9M	169.1M	180.6M	207.6M	218.0M
Net Income From Continuing Ops	50.2M	133.9M	169.1M	180.6M	67.7M	75.5M
Non Operating Income Net Other	20.3M	13.7M	67.8M	24.6M	28.3M	29.7M
Tax Provision	9.9M	(40.4M)	45.6M	33.3M	13.3M	9.1M
Interest Income	10.8M	9.3M	6.7M	11.9M	17.2M	10.1M
Net Interest Income	(43.2M)	(62.3M)	(43.7M)	(37.7M)	(34.2M)	(35.9M)
Reconciled Depreciation	109.5M	116.0M	16.9M	118.3M	123.5M	107.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Integra Stock Analysis

When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Integra Historical Income Statement

About Integra Income Statement Analysis

Integra LifeSciences Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Integra LifeSciences income statement Correlations

Integra LifeSciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Integra LifeSciences income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Integra Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Cost Of Revenue	+ 0.99	Total Revenue
Total Operating Expenses	+ 0.99	Total Revenue
Cost Of Revenue	+ 0.99	Other Operating Expenses
Selling General Administrative	+ 0.98	Gross Profit

Extraordinary Items	- 0.93	Depreciation And Amortization
Net Interest Income	- 0.87	Interest Expense
Discontinued Operations	- 0.81	Non Recurring
Extraordinary Items	- 0.8	Total Revenue
Extraordinary Items	- 0.8	Interest Expense
Extraordinary Items	- 0.79	Total Operating Expenses